Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Absence of Collagen VI Reduces Systolic Function but Paradoxically Increases Ca<sup>2+</sup> Release in the Rat Heart.

Acta physiologica (Oxford, England)·2025
Same author

Single molecule DNA origami nanoarrays with controlled protein orientation.

Biophysics reviews·2024
Same author

Study of the influence of tributyrin-supplemented diets on the gut bacterial communities of rainbow trout (Oncorhynchus mykiss).

Scientific reports·2024
Same author

Evaluation of Genetic or Cellular Impairments in Type I IFN Immunity in a Cohort of Young Adults with Critical COVID-19.

Journal of clinical immunology·2024
Same author

Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.

Leukemia & lymphoma·2023
Same author

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

Acta oncologica (Stockholm, Sweden)·2023

Related Experiment Video

Updated: Apr 8, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Targets for Ibrutinib Beyond B Cell Malignancies.

A Berglöf1, A Hamasy1, S Meinke2

  • 1Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Scandinavian Journal of Immunology
|June 26, 2015
PubMed
Summary

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, shows effects beyond BTK inhibition. Off-target kinase interactions may explain its efficacy and adverse effects, suggesting broader therapeutic potential.

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Related Experiment Videos

Last Updated: Apr 8, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Discovery

Background:

  • Ibrutinib is an irreversible Bruton's tyrosine kinase (BTK) inhibitor approved for B cell malignancies.
  • Initial characterization revealed ibrutinib binds to kinases other than BTK.
  • Understanding these off-target interactions is crucial for optimizing treatment and identifying new applications.

Purpose of the Study:

  • To review the implications of ibrutinib's off-target kinase interactions.
  • To explore how these interactions contribute to both therapeutic effects and adverse events.
  • To predict potential new clinical applications based on non-BTK targets.

Main Methods:

  • Literature review of ibrutinib's pharmacological profile.
  • Analysis of clinical data regarding efficacy and adverse events.
  • Exploration of molecular interactions beyond BTK.

Main Results:

  • Ibrutinib's clinical outcomes may result from combined inhibition of BTK and other kinases.
  • Off-target interactions could explain adverse effects like bleeding and arrhythmias.
  • Long-term treatment may impact bone homeostasis via osteoclast inhibition.

Conclusions:

  • Ibrutinib's effects extend beyond selective BTK inhibition.
  • Off-target binding influences therapeutic efficacy and safety.
  • Further research into non-BTK targets may reveal new therapeutic uses for ibrutinib.